273 related articles for article (PubMed ID: 15522063)
41. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
42. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab.
Hensel M; Ho AD
Am J Hematol; 2003 May; 73(1):37-40. PubMed ID: 12701118
[TBL] [Abstract][Full Text] [Related]
43. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
44. [Hairy cell leukemia treated with cladribine].
Ghanima W; Heldal D; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051
[TBL] [Abstract][Full Text] [Related]
45. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine.
Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M
Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866
[TBL] [Abstract][Full Text] [Related]
46. Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
Robak T
Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083
[TBL] [Abstract][Full Text] [Related]
47. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
48. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
49. Treatment of primary cutaneous B-cell lymphoma with rituximab.
Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
[TBL] [Abstract][Full Text] [Related]
50. Treatment of hairy cell leukemia patients with 2-chloro-2'-deoxyadenosine (2-CdA).
Komarnicki M; Kaźmierczak M; Hansz J
Arch Immunol Ther Exp (Warsz); 1994; 42(1):31-2. PubMed ID: 7503630
[TBL] [Abstract][Full Text] [Related]
51. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
52. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
[TBL] [Abstract][Full Text] [Related]
53. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
54. [Hairy cell leukemia and its treatment with 2-chlorodeoxyadenosine (2-CdA)].
Pawelski S
Acta Haematol Pol; 1995; 26(2):139-43. PubMed ID: 7653218
[TBL] [Abstract][Full Text] [Related]
55. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.
Buckstein R; Patel H; Chesney A; Reis M; Imrie K
Hematology; 2006 Aug; 11(4):267-70. PubMed ID: 17178666
[TBL] [Abstract][Full Text] [Related]
56. Hairy cell leukemia: towards a curative strategy.
Gidron A; Tallman MS
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1153-62. PubMed ID: 16990114
[TBL] [Abstract][Full Text] [Related]
57. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
Palomera L; Domingo JM; Sola C; Azaceta G; Calvo MT; Gutierrez M
Haematologica; 2002 Jan; 87(1):107-8. PubMed ID: 11801472
[No Abstract] [Full Text] [Related]
58. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
59. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up.
Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M
Br J Haematol; 2008 Oct; 143(2):296-8. PubMed ID: 18710384
[No Abstract] [Full Text] [Related]
60. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
